Emergent BioSolutions Inc. reported a net loss of $31.3 million, or $0.58 per share, for the fourth quarter ended December 31, 2024, with adjusted earnings of $0.05 per share. For the full year 2024, the company delivered favorable financial results driven by core products and completed strategic stabilization actions ahead of schedule.
Fourth quarter revenues for NARCAN Nasal Spray decreased by 41%, primarily due to lower over-the-counter and Canadian retail sales. Anthrax MCM product revenues also decreased by 71% due to sales timing, while Smallpox MCM product revenues increased by 565% driven by higher ACAM2000 sales to non-U.S. customers and timing of VIGIV purchases.
Looking ahead, Emergent provided a full-year 2025 financial forecast projecting total revenues between $750 million and $850 million. The company anticipates adjusted EBITDA of $150 million to $200 million and forecasts a return to positive net income, ranging from $16 million to $66 million, with an adjusted gross margin of 48% to 51%.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.